Cytosorbents updates u.s. fda regulatory status of drugsorb-atr

Fda appeal decision found no issues with drugsorb-atr device safety but upheld the de novo denial, and proposes a potential path forward for market authorization princeton, n.j. , aug. 20, 2025 /prnewswire/ -- cytosorbents corporation (nasdaq: ctso), a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery using blood purification, updates the regulatory status of its appeal with the u.s. food and drug administration (fda) for de novo market authorization of drugsorb™-atr.
ATR Ratings Summary
ATR Quant Ranking